Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
Go back to Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference| Anavex Life Sciences Corp. (NASDAQ: AVXL) | Delayed: 2.76 +0.18 (6.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.58 | 52 Week High | $8.30 | |||
| Open | $2.60 | 52 Week Low | $2.43 | |||
| Day High | $2.79 | P/E | N/A | |||
| Day Low | $2.57 | EPS | $-0.22 | |||
| Volume | 1,175,014 | |||||
| Anavex Life Sciences Corp. (NASDAQ: AVXL) | Delayed: 2.76 +0.18 (6.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.58 | 52 Week High | $8.30 | |||
| Open | $2.60 | 52 Week Low | $2.43 | |||
| Day High | $2.79 | P/E | N/A | |||
| Day Low | $2.57 | EPS | $-0.22 | |||
| Volume | 1,175,014 | |||||
